Defense firm V2X, analytics startup Ekkobar among 2026 Mira Award winners
TechPoint announced 17 awards Friday night at its Mira Awards gala in Carmel. The annual awards program recognizes achievements in Indiana’s tech sector.
Eli Lilly and Co.
Complex process leads to a new drug’s identity
The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal analysis and regulatory compliance.
Central Indiana excelling in life sciences, but it needs a brand, speakers say
The region stands out for its prowess in invention and innovation, but competing markets have mastered telling their stories, according to speakers at IBJ’s Life Sciences Power Breakfast.
Insurers balk at Trump’s plan to cover obesity drugs in Medicare
Health insurers are raising questions about the Trump administration’s plan to cover obesity drugs in Medicare next year.
UPDATE: Eli Lilly acquiring Boston-based biotech in deal worth up to $7B
Lilly has been bringing in record revenue from its weight-loss medicines, but continues to diversify its pipeline candidates through acquisitions of biotech companies that are developing new genetic therapies for cancer and other disorders.
What is ‘Ozempic personality’ and why does it make life feel ‘meh’?
The new class of GLP-1 drugs are generally considered safe. Their metabolic effects have been scrutinized in studies, but their psychological impact is far less understood.
Braun administration, Eli Lilly to collaborate on nuclear power development
The Indianapolis-based pharmaceutical giant and the state’s Office of Energy Development signed a nonbinding letter of intent to explore the potential deployment of small modular reactors.
Eli Lilly weight-loss pill Foundayo now available in United States
The Indianapolis-based drugmaker has started shipping the new pill to retail pharmacies.
Trump unveils 100% tariff on some patented drugs on ‘Liberation Day’ anniversary
Trump wrote that he deemed such actions necessary “to address the threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients.”
FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity
The daily oral medication, which will be branded as Foundayo, is expected to begin shipping Monday.
Lilly to acquire UK-based pharmaceutical company in deal worth up to $7.8B
Centessa Pharmaceuticals is developing treatments to address daytime sleepiness and other neurological conditions.
Lilly asks U.S. Supreme Court to rule part of False Claims Act unconstitutional
The Indianapolis-based drugmaker is challenging a $183.7 million judgment in a case brought by a pharmacist who alleged Lilly made false claims about rebates to the federal Medicaid program.
Obesity drug trials complicated by placebo patients leaving early
The companies developing new weight-loss medicines have a problem: People who don’t lose weight quickly figure out they were assigned to take a placebo and are bailing out of their clinical trials.
Lilly’s experimental diabetes shot yields record weight loss in study
The late-stage results handily beat earlier trials of the company’s diabetes blockbuster Mounjaro, which racked up sales of $23 billion in 2025.
Lilly spending $1.8B to update Indianapolis manufacturing operations
The Lilly Technology Center investment includes expanding existing capabilities and the establishment of new production lines.
Lilly introduces direct-to-employer program for weight-loss drug
Eli Lilly and Co. has launched a platform that offers employers coverage options for obesity care through a partnership with 18 digital health programs.
Chief technology officer spent whole career at Lilly
Tim Coleman has held positions within information technology at Lilly in research and development, sales and marketing, manufacturing, and human resources.
CICP launches fund aimed at making Indiana a chemistry hub
The Catalyst Scholars Fund is supported by a $69.4 million grant from Lilly Endowment Inc. to the CICP Foundation Inc. and matching commitments from participating universities.
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy campus
LillyPod, which occupies 30,000 square feet in a room the size of a football field, is capable of crunching massive amounts of data at high speeds and is expected to help the Lilly discover and develop drugs at a faster pace.
GLP-1 fight plays out in statehouses, courthouses
While major drugmakers tussle for market supremacy, they are also taking on compound pharmacies that have not stopped selling obesity drugs despite the end of the shortage of such drugs.